Insmed's ‘win streak' ends as top drug fails study in chronic nasal condition [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
A streak of positive news that pushed Insmed into the ranks of the most valuable biotechnology companies ended this week with the announcement of a failed clinical trial The company's share price dropped almost 17% to about $165 early Thursday, following the announcement late Wednesday. The stock, which was worth around $25 a year and a half ago, had vaulted above $200 in trading this week. The Phase 2b study focused on a drug called brensocatib, which Insmed already sells under the brand name Brinsupri to treat a lung disease known as non-cystic fibrosis bronchiectasis. The company had hoped to expand use of the medicine to include a chronic nasal condition, but researchers found no benefit for either of the two doses they tested. The results reversed what had been a fairly steady climb for Insmed since it first reported promising results for brensocatib in bronchiectasis in May 2024. The company won approval for the drug in August 2025 and then beat analyst estimates for thir
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (NASDAQ:INSM) had its price target lowered by analysts at TD Cowen from $269.00 to $241.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says [Yahoo! Finance]Yahoo! Finance
- Insmed (NASDAQ:INSM) was given a new $230.00 price target on by analysts at HC Wainwright.MarketBeat
- Insmed (NASDAQ:INSM) was given a new $212.00 price target on by analysts at Mizuho.MarketBeat
- Insmed (NASDAQ:INSM) was given a new $241.00 price target on by analysts at Cowen Inc.MarketBeat
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 12/17/25 - Form 8-K
- 12/9/25 - Form 4
- 12/5/25 - Form 144
- INSM's page on the SEC website